Literature DB >> 31136949

RETRACTED: Astragaloside IV protects cardiomyocytes from hypoxia-induced injury by down-regulation of lncRNA GAS5.

Jian Du1, Jia Liu1, Juan Zhen1, Si-Tong Yang1, En-Lai Zheng1, Ji-Yan Leng2.   

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief. Concerns were raised about the background pattern of the Western Blots from Figures 1B and 1E. Given the comments of Dr Elisabeth Bik regarding this article “This paper belongs to a set of over 400 papers (as per February 2020) that share very similar Western blots with tadpole-like shaped bands, the same background pattern, and striking similarities in title structures, paper layout, bar graph design, and - in a subset - flow cytometry panels”, the journal requested the authors to provide the raw data. However, the authors were not able to provide raw data of sufficient quality and detail for the journal to independently audit the provenance and validity of the data, and therefore the Editor-in-Chief decided to retract the article.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Astragaloside IV; Heart failure; Hypoxia injury; PI3K/mTOR; lncRNA GAS5

Mesh:

Substances:

Year:  2019        PMID: 31136949     DOI: 10.1016/j.biopha.2019.109028

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   7.419


  8 in total

1.  The interplay between HIF-1α and long noncoding GAS5 regulates the JAK1/STAT3 signalling pathway in hypoxia-induced injury in myocardial cells.

Authors:  Yanwei Li; Bing Song; Jinlei Liu; Yuqiang Li; Jiebing Wang; Na Liu; Wei Cui
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

2.  Exploring Molecular Mechanism of Huangqi in Treating Heart Failure Using Network Pharmacology.

Authors:  Yan-Gu Tao; Xiu-Fang Huang; Jun-Yan Wang; Meng-Ru Kang; Ling-Jun Wang; Shao-Xiang Xian
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-23       Impact factor: 2.629

3.  Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition.

Authors:  Weibin Qian; Xinrui Cai; Qiuhai Qian
Journal:  Aging (Albany NY)       Date:  2020-03-06       Impact factor: 5.682

4.  Astragaloside IV attenuates hypoxia‑induced pulmonary vascular remodeling via the Notch signaling pathway.

Authors:  Jiamei Yao; Xia Fang; Cui Zhang; Yushu Yang; Dongsheng Wang; Qiong Chen; Guangwei Zhong
Journal:  Mol Med Rep       Date:  2020-11-25       Impact factor: 2.952

5.  Astragaloside IV protects cardiomyocytes against hypoxia injury via HIF-1α and the JAK2/STAT3 pathway.

Authors:  Bei Li; Junjian Yu; Peipei Liu; Taohui Zeng; Xueliang Zeng
Journal:  Ann Transl Med       Date:  2021-09

Review 6.  Astragalus Mongholicus: A review of its anti-fibrosis properties.

Authors:  Fengying Gong; Rongmei Qu; Yongchun Li; Ying Lv; Jingxing Dai
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

7.  LncRNA HIF1A-AS1 contributes to ventricular remodeling after myocardial ischemia/reperfusion injury by adsorption of microRNA-204 to regulating SOCS2 expression.

Authors:  Xiang Xue; Libo Luo
Journal:  Cell Cycle       Date:  2019-08-05       Impact factor: 4.534

Review 8.  Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases.

Authors:  Heng-Wen Chen; Jun Li; Yu-Qing Tan
Journal:  Drug Des Devel Ther       Date:  2020-09-15       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.